NURLF (Neural Therapeutics) Gross Profit: $0.00 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Gross Profit?

Neural Therapeutics NURLF Gross Profit is $0.00 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's gross profit for the three months ended in Jan. 2026 was $0.00 Mil. Neural Therapeutics's gross profit for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Neural Therapeutics's gross profit for the three months ended in Jan. 2026 was $0.00 Mil. Neural Therapeutics's Revenue for the three months ended in Jan. 2026 was $0.00 Mil. Therefore, Neural Therapeutics's Gross Margin % for the quarter that ended in Jan. 2026 was N/A%.

Neural Therapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2026 => No sustainable competitive advantage

Neural Therapeutics  (OTCPK:NURLF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Neural Therapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2026 => No sustainable competitive advantage

Neural Therapeutics Gross Profit Related Terms

Neural Therapeutics Gross Profit Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Gross Profit Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Gross Profit
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NURLF vs VRTX, REGN, MRNA: Gross Profit Comparison

For the Biotechnology subindustry, Neural Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neural Therapeutics Gross Profit vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neural Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Neural Therapeutics's Gross Profit falls into.


Neural Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Neural Therapeutics's Gross Profit for the fiscal year that ended in Jul. 2025 is calculated as

Gross Profit (A: Jul. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Neural Therapeutics's Gross Profit for the quarter that ended in Jan. 2026 is calculated as

Gross Profit (Q: Jan. 2026 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Neural Therapeutics's Gross Margin % for the quarter that ended in Jan. 2026 is calculated as

Gross Margin % (Q: Jan. 2026 )=Gross Profit (Q: Jan. 2026 ) / Revenue (Q: Jan. 2026 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →
What does a Gross Profit of $0.00 Mil mean?
Neural Therapeutics (NURLF) has a Gross Profit of $0.00 Mil as of Jan. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Gross Profit too high?
Neural Therapeutics' current Gross Profit is $0.00 Mil.
How does Neural Therapeutics' Gross Profit compare to VRTX and REGN?
Neural Therapeutics' Gross Profit of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Gross Profit is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Gross Profit of $0.00 Mil. The current Gross Profit is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Gross Profit is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.